|
1.Robertson, D.L., J.P. Anderson, J.A. Bradac, et al., HIV-1 nomenclature proposal. Science, 2000. 288(5463): p. 55-6. 2.Linke, U., AIDS in Africa. Science, 1986. 231(4735): p. 203. 3.Arien, K.K., G. Vanham, and E.J. Arts, Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol, 2007. 5(2): p. 141-51. 4.Lin, K.T., S.H. Huang, C.L. Kao, et al., An autopsy-proved case of AIDS in Taiwan. Asian Pac J Allergy Immunol, 1987. 5(1): p. 25-31. 5.Chen, Y.M., C.M. Lee, R.Y. Lin, and H.J. Chang, Molecular epidemiology and trends of HIV-1 subtypes in Taiwan. J Acquir Immune Defic Syndr Hum Retrovirol, 1998. 19(4): p. 393-402. 6.Chen, Y.M., Y.C. Lan, S.F. Lai, et al., HIV-1 CRF07_BC infections, injecting drug users, Taiwan. Emerg Infect Dis, 2006. 12(4): p. 703-5. 7.Chen, Y.M. and S.H. Kuo, HIV-1 in Taiwan. Lancet, 2007. 369(9562): p. 623-5. 8.Yang, C.H., S.Y. Yang, M.H. Shen, and H.S. Kuo, The changing epidemiology of prevalent diagnosed HIV infections in Taiwan, 1984-2005. Int J Drug Policy, 2008. 19(4): p. 317-23. 9.Huang, Y.F., H.S. Kuo, C.Y. Lew-Ting, et al., Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. Addiction. 106(8): p. 1437-45. 10.Darbyshire, J., Perspectives in drug therapy of HIV infection. Drugs, 1995. 49 Suppl 1: p. 1-3; discussion 38-40. 11.Mansky, L.M., Retrovirus mutation rates and their role in genetic variation. Journal of General Virology, 1998. 79: p. 1337-1345. 12.Rambaut, A., D. Posada, K.A. Crandall, and E.C. Holmes, The causes and consequences of HIV evolution. Nat Rev Genet, 2004. 5(1): p. 52-61. 13.Ho, D.D., Time to hit HIV, early and hard. N Engl J Med, 1995. 333(7): p. 450-1. 14.Guidelines for using antiretroviral agents among HIV-infected adults and adolescents : recommendations of the panel on clinical practices for treatment of HIV. Morbidity and mortality weekly report, recommendations and report vol. 51, no. RR-7. 2002, [Atlanta, GA] [Washington, D.C.]: Epidemiology Program Office, Center for Disease Control and Prevention U.S. Government Printing Office, Superintendent of Documents. 56 p. 15.Patick, A.K. and K.E. Potts, Protease inhibitors as antiviral agents. Clinical Microbiology Reviews, 1998. 11(4): p. 614-+. 16.Pneumocystis pneumonia--Los Angeles. MMWR Morb Mortal Wkly Rep, 1981. 30(21): p. 250-2. 17.Fultz, P.N., A. Srinivasan, C.R. Greene, et al., Superinfection of a chimpanzee with a second strain of human immunodeficiency virus. J Virol, 1987. 61(12): p. 4026-9. 18.Angel, J.B., Y.W. Hu, S. Kravcik, et al., Virological evaluation of the ''Ottawa case'' indicates no evidence for HIV-1 superinfection. AIDS, 2004. 18(2): p. 331-4. 19.Jost, S., M.C. Bernard, L. Kaiser, et al., A patient with HIV-1 superinfection. N Engl J Med, 2002. 347(10): p. 731-6. 20.Ramos, A., D.J. Hu, L. Nguyen, et al., Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol, 2002. 76(15): p. 7444-52. 21.Altfeld, M., T.M. Allen, X.G. Yu, et al., HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature, 2002. 420(6914): p. 434-9. 22.Blackard, J.T., D.E. Cohen, and K.H. Mayer, Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis, 2002. 34(8): p. 1108-14. 23.Hemelaar, J., E. Gouws, P.D. Ghys, S. Osmanov, and W.-U.N.H.I. C, Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS, 2011. 25(5): p. 679-689. 24.Smith, D.M., J.K. Wong, G.K. Hightower, et al., HIV drug resistance acquired through superinfection. AIDS, 2005. 19(12): p. 1251-1256. 25.Ssemwanga, D., F. Lyagoba, N. Ndembi, et al., Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology. 411(1): p. 113-31. 26.Morrison, C.S., P.L. Chen, I. Nankya, et al., Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 57(2): p. 157-64. 27.Rangsin, R., P. Piyaraj, T. Sirisanthana, et al., The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS, 2007. 21 Suppl 6: p. S39-46. 28.Todd, J., J.R. Glynn, M. Marston, et al., Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS, 2007. 21 Suppl 6: p. S55-63. 29.Gottlieb, G.S., D.C. Nickle, M.A. Jensen, et al., Dual HIV-1 infection associated with rapid disease progression. Lancet, 2004. 363(9409): p. 619-22. 30.Clerc, O., S. Colombo, S. Yerly, A. Telenti, and M. Cavassini, HIV-1 elite controllers: beware of super-infections. J Clin Virol. 47(4): p. 376-8. 31.Rachinger, A., T.D. van de Ven, J.A. Burger, H. Schuitemaker, and A.B. van''t Wout, Evaluation of pre-screening methods for the identification of HIV-1 superinfection. Journal of Virological Methods, 2010. 165(2): p. 311-317. 32.Piantadosi, A., M.O. Ngayo, B. Chohan, and J. Overbaugh, Examination of a second region of the HIV type 1 genome reveals additional cases of superinfection. Aids Research and Human Retroviruses, 2008. 24(9): p. 1221-1224. 33.Sanger, F., S. Nicklen, and A.R. Coulson, DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A, 1977. 74(12): p. 5463-7. 34.Heiger, D.N., A.S. Cohen, and B.L. Karger, Separation of DNA restriction fragments by high performance capillary electrophoresis with low and zero crosslinked polyacrylamide using continuous and pulsed electric fields. J Chromatogr, 1990. 516(1): p. 33-48. 35.Pfeifer, G.P., S.D. Steigerwald, P.R. Mueller, B. Wold, and A.D. Riggs, Genomic sequencing and methylation analysis by ligation mediated PCR. Science, 1989. 246(4931): p. 810-3. 36.Drmanac, R., I. Labat, I. Brukner, and R. Crkvenjakov, Sequencing of megabase plus DNA by hybridization: theory of the method. Genomics, 1989. 4(2): p. 114-28. 37.Hyman, E.D., A new method of sequencing DNA. Anal Biochem, 1988. 174(2): p. 423-36. 38.Ahmadian, A., M. Ehn, and S. Hober, Pyrosequencing: history, biochemistry and future. Clin Chim Acta, 2006. 363(1-2): p. 83-94. 39.Tucker, T., M. Marra, and J.M. Friedman, Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet, 2009. 85(2): p. 142-54. 40.Holt, R.A. and S.J. Jones, The new paradigm of flow cell sequencing. Genome Res, 2008. 18(6): p. 839-46. 41.Bentley, D.R., Whole-genome re-sequencing. Curr Opin Genet Dev, 2006. 16(6): p. 545-52. 42.Robertson, D.L., B.H. Hahn, and P.M. Sharp, Recombination in AIDS viruses. J Mol Evol, 1995. 40(3): p. 249-59. 43.Perelson, A.S. and R.M. Ribeiro, Estimating drug efficacy and viral dynamic parameters: HIV and HCV. Stat Med, 2008. 27(23): p. 4647-57. 44.Wang, C., Y. Mitsuya, B. Gharizadeh, M. Ronaghi, and R.W. Shafer, Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res, 2007. 17(8): p. 1195-201. 45.Alteri, C., M.M. Santoro, I. Abbate, et al., ''Sentinel'' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. Journal of Antimicrobial Chemotherapy, 2011. 66(11): p. 2615-2623. 46.Messiaen, P., C. Verhofstede, I. Vandenbroucke, et al., Ultra-Deep Sequencing of HIV-1 Reverse Transcriptase Before Start of an NNRTI-based Regimen in Treatment-naive Patients. Virology, 2012. 426(1): p. 7-11. 47.Mukherjee, R., S.T. Jensen, F. Male, et al., Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS, 2011. 25(16): p. 1951-1959. 48.Swenson, L.C., A. Moores, A.J. Low, et al., Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr. 54(5): p. 506-10. 49.Swenson, L.C., T. Mo, W.W. Dong, et al., Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis. 203(2): p. 237-45. 50.Poon, A.F.Y., R.A. McGovern, T. Mo, et al., Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data. AIDS, 2011. 25(16): p. 2019-2026. 51.Tsibris, A.M., B. Korber, R. Arnaout, et al., Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One, 2009. 4(5): p. e5683. 52.Fischer, W., V.V. Ganusov, E.E. Giorgi, et al., Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One. 5(8): p. e12303. 53.Redd, A.D., A. Collinson-Streng, C. Martens, et al., Identification of HIV Superinfection in Seroconcordant Couples in Rakai, Uganda, by Use of Next-Generation Deep Sequencing. Journal of Clinical Microbiology, 2011. 49(8): p. 2859-2867. 54.MacArthur, M., Viral sex: The nature of AIDS - Goudsmit,J. Library Journal, 1997. 122(7): p. 112-112. 55.Rachinger, A., P. Manyenga, J.A. Burger, et al., Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS. J Infect Dis. 203(11): p. 1621-8. 56.Tsui, R., B.L. Herring, J.D. Barbour, et al., Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol, 2004. 78(1): p. 94-103. 57.Gonzales, M.J., E. Delwart, S.Y. Rhee, et al., Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis, 2003. 188(3): p. 397-405. 58.Soares de Oliveira, A.C., R. Pessoa de Farias, A.C. da Costa, et al., Frequency of subtype B and F1 dual infection in HIV-1 positive, Brazilian men who have sex with men. Virol J. 9: p. 223. 59.Templeton, A.R., M.G. Kramer, J. Jarvis, et al., Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women. Retrovirology, 2009. 6. 60.van der Kuyl, A.C., K. Kozaczynska, R. van den Burg, et al., Triple HIV-1 infection. New England Journal of Medicine, 2005. 352(24): p. 2557-2559. 61.Yang, O.O., E.S. Daar, B.D. Jamieson, et al., Human immunodeficiency virus type 1 clade B superinfection: Evidence for differential immune containment of distinct clade B strains. Journal of Virology, 2005. 79(2): p. 860-868. 62.Jost, S., M.C. Bernard, L. Kaiser, et al., A patient with HIV-1 superinfection. New England Journal of Medicine, 2002. 347(10): p. 731-736. 63.Pernas, M., C. Casado, R. Fuentes, M.J. Perez-Elias, and C. Lopez-Galindez, A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection. Jaids-Journal of Acquired Immune Deficiency Syndromes, 2006. 42(1): p. 12-18. 64.Smith, D.M., M.C. Strain, S.D.W. Frost, et al., Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology, 2006. 355(1): p. 1-5. 65.Kao, C.F., S.Y. Chang, K.T. Hsia, et al., Surveillance of HIV type 1 recent infection and molecular epidemiology among different risk behaviors between 2007 and 2009 after the HIV type 1 CRF07_BC outbreak in Taiwan. AIDS Res Hum Retroviruses. 27(7): p. 745-9. 66.Kanki, P.J., D.J. Hamel, J.L. Sankale, et al., Human immunodeficiency virus type 1 subtypes differ in disease progression. Journal of Infectious Diseases, 1999. 179(1): p. 68-73. 67.Mori, M., B. Sriwanthana, N. Wichukchinda, et al., Unique CRF01_AE Gag CTL epitopes associated with lower HIV-viral load and delayed disease progression in a cohort of HIV-infected Thais. PLoS One. 6(8): p. e22680. 68.Liu, S.L., J.E. Mittler, D.C. Nickle, et al., Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol, 2002. 76(21): p. 10674-84. 69.Brehm, J.H., D. Koontz, J.D. Meteer, et al., Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3''-azido-3''-dideoxythymidine. J Virol, 2007. 81(15): p. 7852-9. 70.Phillips, R.E., S. Rowlandjones, D.F. Nixon, et al., Human-Immunodeficiency-Virus Genetic-Variation That Can Escape Cytotoxic T-Cell Recognition. Nature, 1991. 354(6353): p. 453-459. 71.Klein, M.R., C.A. Vanbaalen, A.M. Holwerda, et al., Kinetics of Gag-Specific Cytotoxic T-Lymphocyte Responses during the Clinical Course of Hiv-1 Infection - a Longitudinal Analysis of Rapid Progressors and Long-Term Asymptomatics. Journal of Experimental Medicine, 1995. 181(4): p. 1365-1372. 72.Mellors, J.W., A. Munoz, J.V. Giorgi, et al., Plasma viral load and CD4(+) lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine, 1997. 126(12): p. 946-954. 73.Saracco, A., M. Musicco, A. Nicolosi, et al., Man-to-woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men. J Acquir Immune Defic Syndr, 1993. 6(5): p. 497-502. 74.de Vincenzi, I., A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med, 1994. 331(6): p. 341-6. 75.Henn, M.R., C.L. Boutwell, P. Charlebois, et al., Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection. Plos Pathogens, 2012. 8(3). 76.Redd, A.D., C.E. Mullis, D. Serwadda, et al., The Rates of HIV Superinfection and Primary HIV Incidence in a General Population in Rakai, Uganda. Journal of Infectious Diseases, 2012. 206(2): p. 267-274.
|